Berner, M. M., Plöger, W. and Burkat, M. (2007). A typology of men’s sexual attitudes, erectile treatment expectations and barriers. Intl J Imp Rsrch, Aug; 19:568-576.
Broderick, G. (2004). Comparative Efficacy and Patient Preferences for PDE-5 Inhibitors. Medscape Urology. Available at: http://www.medscape.org/viewarticle/494277. [Accessed 5 June 2017].
Fleshner, N., Harvey, M., Adomat, H., Wood, C., Eberding, W., Hersey, K. and Guns, E. (2005). Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. J of Ur, Aug; 174(2):636-641.
Gresser, U. and Gleiter, C. H. (2002). Erectile Dysfunction: Comparison of Efficacy and Side Effects of the PDE-5 Inhibitors Sildenafil, Vardenafil and Tadalafil. Eur J Med Res, Oct; 7:435-446.
Tinel, H., Stelte-Ludiwg, B., Hütter, J. and Sandner, P. (2006). Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU, Dec; 98(6): 1259-1263.
Martin-Morales, A. et al (2007). Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol, Feb; 51(2): 541-550.
Moore, R. A., Derry, S. and McQuay, H. J. (2005). Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urology, Dec; 5(18): 1-16.